Adenosine monophosphate–activated protein kinase in diabetic nephropathy

Yaeni Kim, Cheol Whee Park*

Division of Nephrology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

ABSTRACT

Diabetic nephropathy (DN) is the leading cause of end-stage renal disease, and its pathogenesis is complex and has not yet been fully elucidated. Abnormal glucose and lipid metabolism is key to understanding the pathogenesis of DN, which can develop in both type 1 and type 2 diabetes. A hallmark of this disease is the accumulation of glucose and lipids in renal cells, resulting in oxidative and endoplasmic reticulum stress, intracellular hypoxia, and inflammation, eventually leading to glomerulosclerosis and interstitial fibrosis. There is a growing body of evidence demonstrating that dysregulation of 5’-adenosine monophosphate–activated protein kinase (AMPK), an enzyme that plays a principal role in cell growth and cellular energy homeostasis, in relevant tissues is a key component of the development of metabolic syndrome and type 2 diabetes mellitus; thus, targeting this enzyme may ameliorate some pathologic features of this disease. AMPK regulates the coordination of anabolic processes, with its activation proven to improve glucose and lipid homeostasis in insulin-resistant animal models, as well as demonstrating mitochondrial biogenesis and antitumor activity. In this review, we discuss new findings regarding the role of AMPK in the pathogenesis of DN and offer suggestions for feasible clinical use and future studies of the role of AMPK activators in this disorder.

Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Diabetes, especially type 2 diabetes, is now a global epidemic that reflects the harmful consequences of modern lifestyles. Consumption of processed, high-calorie foods, along with physical inactivity, has created an imbalance between energy intake and expenditure [1,2]. This disruption of energy balance is characterized by shifts in lipid and glucose metabolism manifesting as fasting and postprandial hyperglycemia together with dyslipidemia and is further promoted by insulin resistance in a number of tissues [3]. Chronic exposure to glucose overload, free fatty acids, and amino acids can be toxic [4]. Chronic kidney disease (CKD) associated with diabetes is a relatively common manifestation, with both the prevalence and incidence rising in recent years [5]. CKD is the end result of multifactorial processes that mostly stem from deranged glucose and lipid metabolism. This is demonstrated by the increased expression of proteins in relevant signaling pathways and consistent pathologic renal findings. Many studies and experiments have been devised to elucidate the pathogenesis of these metabolic disruptions, although emerging concepts related to such findings remain vast and vague. In an attempt to unravel the core of this disease entity, a growing body of evidence shows that dysregulation of 5’-adenosine
monophosphate-activated protein kinase (AMPK) in relevant tissues is crucial to the development of metabolic syndrome and diabetes [6]. Therefore, targeting this enzyme is a matter of great interest, as it may ameliorate some of the pathologic features of the disease. AMPK regulates the coordination of anabolic processes with its activation proven to improve glucose and lipid homeostasis in insulin-resistant animal models [7,8]. AMPK is strongly expressed in the kidney, where it is involved in diverse physiological and pathologic processes, including ion transport, podocyte function, and diabetic renal hypertrophy. In light of this, we have looked for novel agents that would help to modulate AMPK in an organ-specific manner that targets the diabetic kidney. Instead of providing an exhaustive review of the role of AMPK in these pathologies, this review aims to discuss the mechanisms of AMPK agonists in the context of diabetic nephropathy (DN) and, therefore, shed light on the risks and benefits of currently available and promising future AMPK activators as a treatment option.

AMPK: structure and mechanism of action

AMPK is a metabolic master switch that regulates downstream signals based on shifts in the surrounding energy reservoir [6]. It is expressed in a number of tissues, including the kidney, the liver, the skeletal muscle, the adipose tissue, and the hypothalamus of the brain [9,10]. It is activated when adenosine triphosphate (ATP) consumption causes an increase in the AMP/ATP (or ADP/ATP) ratio. As the ATP level falls, there is an increase in the AMP level, which triggers the activation of the AMPK pathway. The upstream regulator of AMPK, LKB1, allows for AMP phosphorylation at a specific site (Thr-172) on the α subunit of AMPK, which is induced by an increase in intracellular Ca²⁺, is also able to activate AMPK. Of the CaMKK proteins, CaMKKβ has the strongest regulatory effect on AMPK. CaMKKβ regulates AMPK in response to changes in surrounding energy stresses.

Figure 1. Regulation of AMPK by metabolic stress, LKB1, and intracellular Ca²⁺. The AMPK signaling pathway responds to energy stresses that cause fluctuations and imbalances in the AMP/ATP (or ADP/ATP) ratio. As the ATP level falls, there is an increase in the AMP level, which triggers the activation of AMPK.

ACC, acetyl-CoA carboxylase; ADP, adenosine diphosphate; AMP, adenosine monophosphate; AMPK, 5′-adenosine monophosphate-activated protein kinase; ATP, adenosine triphosphate; CaMKKβ, Ca²⁺/calmodulin-dependent protein kinase kinase β; FoxO3, forkhead box O3; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; LKB1, liver kinase B-1; MO25, mouse protein 25; mTOR, mammalian target of rapamycin; NAD, nicotinamide adenine dinucleotide; Nrf, nuclear respiratory factor; PGC-1α, peroxisome proliferator-activated receptor-gamma coactivator 1α; PFK2, phosphofructokinase 2; PP2A, protein phosphatase 2A; PP2C, protein phosphatase 2C; SIRTs, sirtuins; STRAD, STE-related adaptor; Thr-172, threonine-172; TSC2, tuberous sclerosis complex 2.
inhibition of anabolic energy-consuming pathways, as well as the stimulation of catabolic, energy-producing pathways [11]. AMPK is a heterotrimer consisting of a catalytic \( \alpha \) subunit (\( \alpha 1 \) and \( \alpha 2 \)) and regulatory \( \beta (\beta 1 \) and \( \beta 2 \)) and \( \gamma \) subunits (\( \gamma 1, \gamma 2, \) and \( \gamma 3 \)). Its isoforms are tissue specific [15]. The \( \gamma \) subunit includes 4 distinct cystathionine beta synthase domains that perceive shifts in the AMP-to-ATP ratio, conferring the ability to switch AMPK on and off [16]. The \( \alpha \) subunit is a catalytic domain with its activating loop at threonine-172 (Thr-172) that switches on as it gets phosphorylated by upstream AMPK [17]. Ser485 of the subunit exerts its inhibitory action via phosphorylation by Akt or protein kinase A or by autophosphorylation [18]. “ST loop,” a serine/threonine—rich insert of C-terminal domains of the \( \alpha \) subunit, appears to contain several regulatory phosphorylation sites, which block access to upstream kinases [16]. AMPK activation can be triggered when the following conditions are fulfilled. First, increased levels of AMP binding to the \( \gamma \) subunit incur conformational change that exposes the active site Thr-172 on the \( \alpha \) subunit, making it a better substrate for upstream kinases. Second, phosphorylation of the activating loop of the \( \alpha \) subunit by an upstream kinase is required. This combination of allosteric activation and phosphorylation of the stimulatory site leads to the accentuation of AMPK activity to levels greater than 1,000-fold [15,17].

Activated AMPK then phosphorylates its main downstream targets, acetyl-CoA carboxylase (ACC) and hydroxy-methylglutaryl CoA reductase (HMGCR), which are primarily involved in the rate-limiting steps of lipid homeostasis. Phosphorylation at serine 79 (Ser79) exerts inhibitory action by preventing the conversion of acetyl-CoA to malonyl-CoA, further encouraging the oxidation of fatty acids. Other downstream targets of AMPK include tuberous sclerosis complex protein-2, which is associated with cell growth and autophagy [19], and peroxisome proliferator—activated receptor-gamma coactivator-1\( \alpha \) (PGC-1\( \alpha \)), which hinders protein synthesis by inhibiting the mammalian target of rapamycin (mTOR) complex 1 [19], in turn inhibiting cholesterol synthesis and stimulating mitochondrial biogenesis (Fig. 1). Overall, these downstream targets of AMPK are expected to have favorable effects on DN by maintaining metabolic homeostasis.

The role of AMPK beyond energy homeostasis: regulating metabolism

AMPK plays a major role in glucose homeostasis by modulating glucose transport in peripheral tissues [20]. Skeletal muscle, one of the main peripheral tissues involved in glucose uptake and disposal, expresses glucose transporter type 4 (GLUT4). In hyperglycemia, insulin promotes the translocation of intracellular vesicular GLUT4 to the cell membrane, thereby increasing glucose uptake in the muscle [6]. AMPK activation contributes to glucose transport in a similar way as insulin. The result is AMPK-induced glucose uptake stimulation in skeletal cells, with increased expression of enzymes specialized in glucose uptake such as GLUT4 and hexokinase II [6]. Moreover, AMPK directly phosphorylates the GLUT4 enhancer factor that is essential in the regulation of GLUT4 expression. Hexokinase phosphorylates glucose entering the cell, allowing for a structural change that prevents glucose from leaving the cell in the first step of glycolysis. Overall, these sequential alterations in the expression of enzymes involved in glucose uptake are the ultimate result of AMPK activation, which stimulates catabolic processes that counter the deleterious effects of glucose excess and maintains energy homeostasis.

Hyperglycemia is a causative factor in the development of DN through its detrimental effects on glomerular and mesangial cells. Some in vitro studies have demonstrated its association with mesangial cell proliferation and hypertrophy, along with increased matrix production and basement membrane thickening [21]. Moreover, hyperglycemia—induced upregulation of vascular endothelial growth factor expression in podocytes increases vascular permeability [21]. In addition to these changes, classical pathways involving the production of advanced glycosylation end products, activation of protein kinase C, and reinforcement of the aldose reductase pathway contribute to the development of DN, in which oxidative stress appears to be a common theme [22,23]. In this regard, targeting AMPK in DN could ameliorate these adverse effects by regulating glucose-induced oxidative stress metabolism [4]. There is growing evidence regarding the role of AMPK in mediating intracellular signaling pathways, that is, the alteration of cellular redox state and antioxidant enzyme expression via the AMPK transcriptional activity of class O forkhead box (FoxO) signaling pathway [23]. FoxO proteins are an evolutionary conserved subfamily of transcriptional factors involved in the regulation of energy metabolism. In detail, it increases the expression of antioxidant enzymes, promotes mitochondrial biogenesis, cell survival, and longevity in several tissues, and even participates in tumor suppression [22]. The transcriptional activity of FoxO3a, one of the 4 members of the family consisting of FoxO1, FoxO3, FoxO4, and FoxO6, is further modulated by AMPK in response to metabolic stress. Moreover, FoxO3a is known to shield quiescent cells from reactive oxygen species (ROS) by antagonizing apoptosis through which oxidative stress is reduced by directly increasing their quantities of manganese superoxide dismutase (SOD) messenger RNA and protein [21]. It is well known that the activity of autophagic process is closely related to changes in the production of ROS. Although mild oxidative stress—induced autophagic process is beneficial for cell survival, excessive oxidative damage caused by high ROS would bypass autophagy induction and evoke apoptosis or necrosis, leading to promote cell death [24]. Antioxidant enzymes, including thioredoxin, peroxiredoxin, Mn—SOD, and catalase, are found to be upregulated on activation of the AMPK—FoxO3a signaling pathway [25]. Therefore, on ROS exposure, AMPK, silent information regulator T1 (SIRT1), a well—known FoxO3a coactivator [26], and FoxO3a are expected to intertwine closely to regulate the apoptotic and autophagy crosstalk [22].

AMPK modulates changes in lipid metabolism via the regulation of fatty acid oxidation and cholesterol synthesis in the liver. The key enzymes involved include ACC and HMGCR [27,28]. Both participate in the rate—limiting steps of fatty acid and cholesterol synthesis and are inactivated on phosphorylation by AMPK. Catabolism is induced by fatty acid beta-oxidation, leading to the production of acetyl-CoA, which then joins the citric acid cycle to generate ATP. On the other hand, fatty acid synthesis is a multistep, energy—consuming, anabolic process that generates fatty acids from acetyl-CoA and malonyl-CoA. Likewise, cholesterol is synthesized from acetyl-CoA to produce 3—hydroxy—3—methylglutaryl—coenzyme A (HMGCoA), which is then converted into mevalonate through an anabolic process that consumes ATP. Hence, in response to energy depletion, the inhibition of ACC by AMPK results in a fall in malonyl-CoA levels and subsequently interrupts fatty
acid synthesis, facilitating the acceleration of fatty acid oxidation. Through the activation of malonyl-CoA decarboxylase, AMPK brings about a decrease in malonyl-CoA levels and an increase in fatty acid oxidation. Likewise, HMGCR is inactivated on phosphorylation, which leads to a reduction in cholesterol synthesis. In addition, the expression of such genes as fatty acid synthase, pyruvate kinase, ACC, and sterol regulatory element binding protein-1 (SREBP-1) is lipogenesis associated and suppressed by AMPK in states of energy deficit [29].

Emerging evidence indicates that renal lipid dysregulation is a major causative factor in the development of CKD, along with DN [30]. Recently, it has been characterized by tubular rather than glomerular lipid accumulation, attributable to decreased lipid uptake, increased renal lipid synthesis, and defective fatty acid utilization in the renal physiology [19]. Systemic and intrarenal alterations in lipid metabolism are reflected by increased triglycerides and low-density lipoprotein levels, decreased high-density lipoprotein levels, increased expression of SREBP-1 and fatty acid synthase, and decreased expression of carnitine palmitoyltransferase I, which is involved in the rate-limiting step of fatty acid oxidation [31]. AMPK inhibits lipogenesis and enhances fatty acid oxidation through targets such as SREBP, ACC, fatty acid synthase, and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) in various tissues. This raises the potential for AMPK activation as a therapeutic target in optimizing lipid metabolism in DN [32].

AMPK perceives shifts in the surrounding energy reservoir and adapts to the nutrient supply status by promoting a cellular response. It participates in protein synthesis by regulating protein translation. Its main targets are cytoplasmic substrates, such as eukaryotic elongation factor 2 and mTOR, which modulate the stimulation of cellular processes that aid cell growth in states of nutritional surplus [33]. On AMPK-dependent phosphorylation of these substrates, repression of protein synthesis ensues. It could be useful to coordinate these processes in DN as they correlate with diminished AMPK activity, resulting in increases in protein synthesis that can cause diabetes-induced renal hypertrophy in hyperglycemic conditions. Thus, specifically stimulating cytoplasmic AMPK could provide a more focused approach in alleviating diabetes-induced renal damage [34].

Figure 2. Representative signaling in the AMPK pathway by various AMPK activators. Schematic diagram of selected physiological effects of AMPK activators on mitochondrial biogenesis, glucose and lipid metabolism, and antitumor activity. AICAR, 5-aminooimidazole-4-carboxamide ribonucleoside; AMP, adenosine monophosphate; AMPK, 5’ adenosine monophosphate activated protein kinase; ATP, adenosine triphosphate; CaMKβ, Ca2+/calmodulin-dependent protein kinase β; FoxOs, forkhead transcription factors; LKB1, liver kinase B-1; mTOR, mammalian target of rapamycin; NAD, nicotinamide adenine dinucleotide; NF-κB, nuclear factor kappaB; PGC-1α, peroxisome proliferator activated receptor-gamma coactivator 1α; SIRT1, silent information regulator T1.
Managing DN by targeting the AMPK pathway

In parallel with a vast and rapidly growing body of knowledge on the favorable effects of AMPK, of which only a fragment has been discussed, investigators have devised several pharmaceutical agents in the search for naturally occurring compounds that could activate AMPK with minimal toxicity. We will introduce some conventional AMPK activators, along with our data on new therapeutic agents used to experimentally treat diabetic mouse models addressing DN (Figs. 2, 3).

Conventional AMPK activators

5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR) is an adenosine analogue that is frequently demonstrated in animal models as it recapitulates AMP in the course of being metabolized to phosphorylated AICA riboside or AICA ribotide [AICAR 5-monophosphate (ZMP)] (Fig. 2) [35]. ZMP binding to the γ subunit of AMPK directly activates AMPK via 3 mechanisms: accelerating phosphorylation, inhibiting dephosphorylation, and allosterical activation [35,36]. AICAR upregulates genes associated with oxidative metabolism, angiogenesis, and glucose sparing, thereby improving glucose homeostasis in obese, insulin-resistant rats [37]. Moreover, a recent report on chronic AICAR treatment shows its efficacy in preventing unfavorable functional and morphologic changes in mice raised on high-fat diets, with regard to renal cholesterol and phospholipid accumulation and lysosomal system dysfunction; this demonstrates that AICAR in a viable form may be a promising agent in alleviating the deleterious outcomes of DN [38].

Metformin’s pluripotent roles are alluded to in terms of its antitumorigenic, glucose-lowering, and cardioprotective effects, which are due in part to its upregulation of AMPK activity [39,40]. Metformin’s glucose-lowering effect is a result of reduced hepatic gluconeogenesis, whereas improved insulin sensitivity is mediated by the activation of the LKB1–AMPK axis [41]. It is suggested that metformin activates AMPK indirectly by inhibiting relevant cells from entering the mitochondrial respiratory chain, facilitating a switch from aerobic to anaerobic glycolysis in a manner that raises the cellular AMP-to-ATP ratio (Fig. 2) [42]. In addition, mounting evidence indicates that metformin-induced inactivation of mTOR by AMPK is associated with suppressed cell proliferation and increased autophagy, which are thought to lower cancer incidence [43]. Stimulation of AMPK activity with AICAR or metformin also resulted in inhibition of renal hypertrophy due in part to the prevention of glucose-induced protein synthesis. This was associated with decreases in the phosphorylation of Akt, mTOR, p70S6 kinase, and 4E-BP1 in renal cells, suggesting

Figure 3. Proposed renoprotective mechanisms in diabetic nephropathy by known and novel AMPK activators. Treatment with AMPK activators reduces albuminuria, glomerulosclerosis, and tubulointerstitial fibrosis in types 1 and 2 diabetic nephropathy by exerting effects on mitochondrial biogenesis, peroxisomal β-oxidation, oxidative stress, and lipogenesis through the activation of AMPK-SIRT1 signaling. AICAR, 5-aminoimidazole-4-carboxamide ribonucleoside; AMPK, 5′ adenosine monophosphate–activated protein kinase; ChREBP, carbohydrate regulatory element–binding protein; ECM, extracellular matrix; FoxOs, forkhead transcription factors; PGC–1z, peroxisome proliferator–activated receptor coactivator 1z; PPARs, peroxisome proliferator–activated receptors; SIRT1, silent information regulator T1; SREBP, sterol regulatory element–binding protein.
that AMPK regulates the initiation and elongation phases of translation [44].

Adiponectin, an adipose tissue-derived cytokine, is another AMPK activator. Decreases in the plasma level of adiponectin have been correlated with insulin resistance and obesity. In diabetes, reduced AMPK activity was noted to be associated with the renal accumulation of triglyceride and glycogen, which reflects the pathogenesis of diabetic renal hypertrophy [43]. Furthermore, adiponectin knockout mice exhibit increased albuminuria and fusion of the podocyte foot process [46]. In cultured podocytes, both adiponectin and AMPK activation reduced podocyte permeability to albumin, further ameliorating podocyte dysfunction. These effects are mostly due to the reduction of oxidative stress, with subsequent decreases in the level of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4 in podocytes [46]. Another study showed that adiponectin receptor 1 and catalytic AMPK subunits α1 and α2 were localized to the glomeruli in endothelial, mesangial, podocyte, and parietal epithelial cells of Bowman capsule. The incubation of freshly isolated glomeruli with adiponectin led to the activation of AMPK via phosphorylation of its catalytic domain [47].

Resveratrol is a naturally occurring plant polyphenol that may target aging and obesity-related chronic diseases by preventing inflammation and oxidative stress [48]. It activates SIRT1, a nicotinamide adenine dinucleotide-dependent protein deacetylase, and AMPK (Fig. 2). Resveratrol’s subsequent activation of downstream targets is expected to have some renoprotective effects involving changes in catabolic metabolism, mitochondrial activation, and angiogenesis, as well as enhanced cell survival [49–51]. Resveratrol’s renoprotective effects with regard to oxidative stress and proinflammatory reactions are demonstrated in the attenuation of diabetes-induced superoxide anion, protein carbonyl levels, and cytokines interleukin-1β, tumor necrosis factor-α, and interleukin-6, which are associated with increased AMPK phosphorylation in diabetic renal tissues [52]. Moreover, in our previous experiment, db/db mice treated with resveratrol demonstrated improvements in not only renal functional parameters but also pathologic features. This manifestation was consistent with increases in the phosphorylation of AMPK, activation of SIRT1–PGC-1α signaling, and activation of the key downstream effector, PPARα–estrogen-related receptor (ERR)-1α–SREBP-1c. In addition, resveratrol reduced the activity of phosphatidylinositol-3 kinase-Akt phosphorylation and FoxO3a phosphorylation, which further caused a decrease in B-cell leukemia/lymphoma 2 (BCL-2)–associated X protein and increases in BCL-2, SOD1 and SOD2 production. In cultured mesangial cells, resveratrol attenuated renal apoptotic changes further, preventing high-glucose-induced oxidative stress and apoptosis through the phosphorylation of AMPK and activation of SIRT1–PGC-1α signaling and the downstream effector, PPARα–ERR-1α–SREBP1c. The results suggest that resveratrol prevents DN in db/db mice through the phosphorylation of AMPK and activation of SIRT1–PGC-1α signaling, which seem to prevent lipotoxicity-related apoptosis and oxidative stress in the kidney [8].

New AMPK activators

Fenofibrate is a drug of the fibrate class used for the treatment of dyslipidemia [53] but is also an agent that could alleviate DN-induced alterations through AMPK activation (Fig. 2). Streptozotocin-induced diabetic rats treated with fenofibrate improved in not only renal functional parameters but also hyperglycemia-induced oxidative damage, as indicated by significantly increased levels of glutathione and catalase together with a noticeable decrease in lipid peroxidation. Fenofibrate’s protective role in DN is in ameliorating endothelial dysfunction via increased modulation of AMPK, LKB1, and endothelial nitric oxide synthase (eNOS) expression [54]. In parallel with this, our previous experiments on the diabetic mouse model have demonstrated that fenofibrate can ameliorate albuminuria, glomerular matrix expansion, and inflammatory cell infiltration in the glomeruli and inhibit the accumulation of intrarenal free fatty acids and triglycerides. These results are compatible with the increased expression of PPARα and the activation of AMPK, PGC1α–ERR1α–pACC, as well as the suppression of SREBP-1c and carbohydrate regulatory element–binding protein-1, which constitutes the main downstream effector in lipid metabolism. Fenofibrate decreased the phosphorylation of phosphatidylinositol-3 kinase-Akt and FoxO3a in the kidneys, resulting in the demonstrated BCL-2–to-BCL-2–associated X protein ratio and SOD1 levels. Such findings were reproducible in cultured mesangial cells as reflected by the prevention of high-glucose–induced apoptosis and oxidative stress via AMPK phosphorylation, PGC-1α–ERR-1α activation, and SREBP-1c and carbohydrate regulatory element–binding protein-1 suppression. Our results suggest that fenofibrate’s potential as a therapeutic modality for DN lies in its ability to improve lipotoxicity by stimulating AMPK-PGC-1α–ERR-1α–FoxO3a signaling [55].

Anthocyanin, a flavonoid in the polyphenol class, is a major constituent of food color and has been reported to possess both antidiabetic and antioxidant properties [56]. As its beneficial effects on lipid metabolism are dependent on AMPK activation (Fig. 2) [57], we were prompted to investigate whether an anthocyanin–rich Seoritea extract could ameliorate DN in db/db mice. Indeed, anthocyanin ameliorated intrarenal lipid accumulation with attenuations of mesangial expansion and glomerular inflammation; these effects appear to be attributable to the increased phosphorylation of AMPK, activation of PPARα and peroxisome proliferator–activated receptor-gamma, and inhibitory activity of ACC and SREBP-1c, leading to a reduction in lipotoxicity in the kidney. In cultured human glomerular endothelial cells, anthocyanin prevented high-glucose–induced oxidative stress and apoptosis via activation of AMPK in the same manner. The results indicate that anthocyanin could help alleviate some of the pathologic features of DN as it prevents lipotoxicity-related apoptosis and oxidative stress in the diabetic kidney through the activation of AMPK and its downstream effectors [58].

Cinacalcet is a calcimimetic that positively modulates the calcium-sensing receptor (CaSR). It is mainly used in the treatment of secondary hyperparathyroidism in CKD patients as it both diminishes the inhibitory effect of parathyroid hormone on renal phosphate reabsorption and inhibits renal calcium excretion [59]. However, some recent reports have demonstrated that CaSRs are expressed in human endothelial cells and that their stimulation by cinacalcet induces nitric oxide (NO) production, resulting in vasorelaxation [60]. Moreover, calcimimetics significantly increased intracellular Ca$^{2+}$ levels, which in turn augmented NO release via a time- and Ca$^{2+}$–dependent increase in eNOS-ser1177 phosphorylation activity
Based on these findings, we proposed that DN-induced endothelial dysfunction could be ameliorated by the activation of eNOS—NO as a result of cinacalcet administration (unpublished observations). Our preliminary work shows that cinacalcet reduced albuminuria without influencing either blood glucose or Ca$^{2+}$ concentration and ameliorated mesangial expansion and inflammatory cell infiltration in the glomerulus of db/db mice. In the renal cortex, cinacalcet increased the expression of CaSR and the phosphorylation of CaMKKβ and LKB1. Subsequent activation of AMPK was followed by the activation of PGC-1α and phospho-Ser1177 eNOS—NO (Fig. 2). In vitro studies were consistent with the fact that cinacalcet decreases oxidative stress and apoptosis; this effect is attributable to increases in intracellular Ca$^{2+}$ and the phosphorylation of CaMKKβ, LKB1, and AMPK. All these changes were associated with an increase in the phosphorylation of eNOS. Overall, our results suggest that cinacalcet changes were associated with an increase in the phosphorylation of eNOS.

AdipoRon is an orally active, synthetic small molecule that activates adiponectin receptor (AdipoR). It mimics the antidiabetic effects of adiponectin, exhibiting its effect through the activation of AMPK and PPARαx pathways via AdipoR1 and AdipoR2, respectively (Fig. 2) [62]. AdipoR activation has recently become a promising treatment for diabetes, nonalcoholic fatty liver disease, and cardiovascular disease, demonstrating anti-inflammatory actions in macrophages and cytoprotective effects on pancreatic β-cells [63]. However, mice overexpressing adiponectin are found to have reduced bone density [64], heart damage (left ventricular hypertrophy) [65], increased angiogenesis and adipogenesis [65], and infertility [66]. Despite these concerns, AdipoRon appears to be neutral and actually prolongs the life span in db/db mice [62]. Our unpublished data suggest that AdipoRon-treated db/db mice exhibit improvements in DN associated with increased expression of AdipoR1 and AdipoR2 in the glomerulus and consistent upregulation of phosphorylated AMPK, PPARαx, and their downstream target molecules (unpublished observations). With respect to renal ultrastructure, AdipoRon treatment is associated with a noticeable reversal of diabetes-induced glomerular basement membrane (GBM) thickening, foot process widening, and slit diaphragm space narrowing; furthermore, it decreased glomerular matrix expansion and inflammation. AdipoRon may control oxidative stress in the glomerulus through AMPK- and PPARαx-activated pathways, helping to prevent the deterioration of renal function. The protective role of AdipoRon against the development of albuminuria appears to occur through direct action on podocytes, independent of the systemic effects of adiponectin. Its reduction of oxidative stress confers protection against albuminuria and podocyte damage, ameliorating endothelial dysfunction in DN. Therefore, AdipoRon is a novel, promising therapeutic agent in preventing and ameliorating DN, particularly in type 2 diabetes.

**Conclusion and future perspectives**

Despite progress in the field of pharmacologic therapies that aims to prevent or delay the progression of DN, the number of end-stage renal disease patients is rising steadily, especially in Korea [5,67]. Therefore, the development of new therapeutic agents is of crucial concern to public health. Mounting evidence suggests that AMPK activation in various tissues can help achieve metabolic homeostasis, with subsequent improvements in glucose and lipid profiles. We have summarized the role of AMPK activation in the context of several known and new activators that can treat DN by preventing renal fibrosis, extra-cellular matrix accumulation, apoptosis, and inflammation in the kidney (Fig. 3). However, a major pitfall in the use of AMPK activators is their as-yet-unknown adverse effects, which may counter the therapeutic effects we are aiming for. Such off-target effects involve AMPK’s possible role in the stimulation of food intake through the activation of AMPK expressed in certain nuclei of the hypothalamus [68]. This provides a clear example of the need for both target and tissue specificity. Pharmacologic activation of AMPK needs to be achieved tissue specifically, and the isoforms of AMPK expressed in different tissues need to be identified [69]. In addition, we must determine the effective dose with least toxicity that can still produce detectable AMPK activation to achieve adequate metabolic regulation. The evidence of the metabolic effects of AMPK signifies just the beginning of the field, with significant challenges lying ahead in the translation of these data into feasible therapeutics for DN and obesity-related metabolic disease [5].

**Conflicts of interest**

All authors have no conflicts of interest to declare.

**Acknowledgments**

This study was supported by grants from the Basic Science Research Program through the National Research Foundation of Korea funded by the Research Fund of Seoul St. Mary’s Hospital, the Catholic University of Korea (C.W.P.).

**References**

[1] Willett WC: Dietary fat plays a major role in obesity: no. Obes Rev 3:59–68, 2002
[2] Gross LS, Li L, Ford ES, Liu S: Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J Clin Nutr 79:774–779, 2004
[3] Violette B, Lantier L, Devin-Leclerc J, Hebrard S, Amouyal C, Mounier R, Foretz M, Andreelli F: Targeting the AMPK pathway for the treatment of type 2 diabetes. Front Biosci (Landmark Ed) 14: 3380–3400, 2009
[4] Dronavalli S, Duka I, Bakris GL: The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 4:444–452, 2008
[5] Park CW: Diabetic kidney disease: from epidemiology to clinical perspectives. Diabetes Metab J 38:252–260, 2014
[6] Hardie DG, Ross FA, Hawley SA: AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13: 251–262, 2012
[7] Hallows KR, Mount PF, Pastor-Soler NM, Power DA: Role of the energy sensor AMP-activated protein kinase in renal physiology and disease. Am J Physiol Renal Physiol 298:F1067–F1077, 2010
[8] Kim MY, Lim JH, Youn HH, Hong YA, Yang KS, Park HS, Chung S, Ko SH, Shin SJ, Choi BS, Kim HW, Kim YS, Lee JH, Chang YS, Park CW: Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice. Diabetologia 56:204–217, 2013
[9] Andersson U, Filipsson K, Abbott CR, Woods A, Smith K, Bloom SR, Carling D, Small CJ: AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem 279:12005–12008, 2004
[10] Kubota N, Yano W, Kubota T, Yamauuchi T, Itchi S, Kumagai H, Kozono H, Takamoto I, Okamoto S, Shiuchi T, Suzuki R, Satoh H, Tsuchida A, Moroi M, Sugi K, Noda T, Ebinuma H, Ueta Y, Kondo T, Araki E, Ezaki O, Nagai R, Toke K, Terauchi Y, Ueki K, Minokoshiba Y, Kadowaki T: Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 6:55-68, 2007

[11] Hardie DG, Scott JW, Pan DA, Hudson ER: Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 546: 113-120, 2003

[12] Hawley SA, Boudreau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR, Hardie DG: Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol Chem 28:28, 2003

[13] Hawley SA, Selbert MA, Goldstein EG, Edelman AM, Carling D, Hardie DG: 5′-AMP activates the AMP-activated protein kinase cascade, and Ca2+ /calmodulin activates the calcmodulin-dependent protein kinase I cascade, via three independent mechanisms. J Biol Chem 270:27186-27191, 1995

[14] Momcilovic M, Hong SP, Carlson M: Mammalian TAK1 activates the mammalian target of rapamycin (mTOR) by phosphorylating its regulatory subunit, mLST8. J Biol Chem 281:25343-25348, 2006

[15] Harding HG, Ashford ML: AMPK: regulating energy balance at the cellular and whole body levels. Physiology (Bethesda) 29:99-107, 2014

[16] Xiao B, Heath R, Saiu P, Leiper FC, Leone P, Jing C, Walker PA, Gowans GJ, Hawley SA, Ross FA, Hardie DG: AMP is a true physiological AMPK activator. J Biol Chem 281:25353-25360, 2006

[17] Cowans GJ, Hawley SA, Ross FA, Hardie DG: AMP is a true physiological regulator of AMPK-activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metab 18:556-566, 2013

[18] Hormann S, Vertommen D, Heath R, Neumann D, Mouton V, Woods A, Schlattner U, Wallimann T, Carling D, Hare L, Rider MH: AMPK antagonizes ischemia-induced Thr172 phosphorylation of AMPK-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J Biol Chem 281:5335-5340, 2006

[19] Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, Carling D: Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 282:32539-32548, 2007

[20] Jensen TE, Sylow L, Rose AJ, Madsen AB, Angin Y, Maarbjerg SJ, Richter EA: Contraction-stimulated glucose transport in muscle is controlled by AMPK and mechanical stress but not sarcoplasmic reticulum Ca2+ release. Mol Metab 3:742-753, 2014

[21] Kops GJ, Dansen TB, Polderman PE, Saarloos L, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH, Burgering BM: Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419:316-321, 2002

[22] Wu SB, Wu YT, Wu TP, Wei YH: Role of AMPK-mediated adaptive responses in human cells with mitochondrial dysfunction to oxidative stress. Biochem Biophys Acta 1840:1331-1344, 2014

[23] Stadler K, Goldberg IJ, Susztak K: The evolving understanding of lipotoxicity. Curr Diab Rep 12:28, 2012

[24] Chen SF, Raibon A, Cornille K, Gay S, Bernardi H, Candau R: AMPK promotes skeletal muscle autophagy through activation of forkhead FoxO3a and interaction with Ulk1. J Cell Biochem 113:695-710, 2012

[25] Filomeni G, Desideri E, Cardaci S, Rotilio G, Cirriolo MR: Under the ROS...thiol network is the principal suspect for autophagy commitment. Autophagy 6:999-1005, 2010

[26] Zrelli H, Matsuoka M, Kitazaki S, Zarrouk M, Miyazaki H: Hydroxytyrosol reduces intracellular reactive oxygen species levels in vascular endothelial cells by upregulating catalase expression through the AMPK-FOXO3A pathway. Eur J Pharmacol 660:275-282, 2011

[27] Hayashi T, Hirshman MF, Kurth EJ, Winder WW, Goodyear LJ: Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 47: 1369-1373, 1998

[28] Ouchi N, Shibata R, Walsh K: AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. Circ Res 96:838-846, 2005

[29] Li Y, Xu S, Mihaylova MM, Zhang B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, Gao B, Wierzbiicki M, Verbeuren TJ, Shaw RJ, Cohen RA, Zhang M: AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13:376-388, 2011

[30] Weinberg JM: Lipotoxicity. Kidney Int 70:1560-1566, 2006

[31] Ginsberg HN: Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes 45(Suppl 3):S27-S30, 1996

[32] Stadler K, Goldberg IJ, Susztak K: The evolving understanding of the contribution of lipid metabolism to diabetic kidney disease. Curr Diab Rep 15:40, 2015

[33] Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM: AMPK and PPARdelta agonists are exercise mimetics. Cell 134:405-415, 2008

[34] Declèves AE, Zolkipi Z, Satriano J, Wang L, Nakayama T, Rogac M, Le TP, Nortier JL, Farquhar MG, Naviaux RK, Sharma K: Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury. Kidney Int 85:611-623, 2014

[35] Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745-6752, 2007

[36] El Messaoudi S, Rongen GA, Riksen NP: Metformin therapy in diabetes: the role of cardioprotection. Curr Atheroscler Rep 15:314, 2013

[37] Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F: Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 121:253-270, 2012

[38] DeBerardinis RJ, Acosta MN, Borenstein AE, Zolkipli Z, Satriano J, Wang L, Nakayama T, Rogac M, Le TP, Nortier JL, Farquhar MG, Naviaux RK, Sharma K: Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury. Kidney Int 85:611-623, 2014

[39] Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745-6752, 2007

[40] El Messaoudi S, Rongen GA, Riksen NP: Metformin therapy in diabetes: the role of cardioprotection. Curr Atheroscler Rep 15:314, 2013

[41] Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F: Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 121:253-270, 2012

[42] El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275:223-228, 2000

[43] Vazquez-Martín A, Olivares-Ferreros C, Cufi S, Martín-Castillo B, López-Cascales C, Carmona-Poyatos J, Prieto G, Varela-Ferreira A, Navia M, Fernández-Gómez J, Navia R, Cordero-Merino J, Ortego-Díaz A, Menéndez JA: Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. Curr Mol Med 10:674-691, 2010

[44] Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, Foretz M, Viollet B, Weinberg JM, Choudhury GG, Kasinath BS: A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 292:F617-F627, 2007

Kidney Res Clin Pract 35 (2016) 69–77
Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, Ouedraogo R, Hough K, McCue P, Chan L, Falkner B, Goldstein BJ: Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118:1645–1656, 2008

Cammisotto PG, Bendayan M: Adiponectin stimulates phosphorylation of AMP-activated protein kinase alpha in renal glomeruli. J Mol Histol 39:579–584, 2008

Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Cammisotto PG, Bendayan M: Adiponectin stimulates phosphorylation of AMP-activated protein kinase alpha in renal glomeruli. J Mol Histol 39:579–584, 2008

Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME: Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Cell 127:1109–1122, 2006

Brunet A, Sweeney LB, Sturgill JF, Chua KE, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME: Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303:2011–2015, 2004

Rodgers JT, Lerin C, Hasa W, Gygi SP, Spiegelman BM, Puigserver P: Nutrient control of glucose homeostasis through a complex of activating SIRT1 and PGC-1alpha. Nat Rev Mol Cell Biol 11:579–591, 2010

Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW: Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. Embo J 23:2369–2380, 2004

Chang CC, Chang CY, Wu YT, Huang JP, Yen TH, Hung LM: Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase. J Biomed Sci 18:47, 2011

Yang LP, Keating GM: Fenofibrate: clinical use in combination therapy of the treatment of mixed dyslipidemia. Am J Cardiovasc Drugs 9:401–409, 2009

Al-Rasheed NM, Al-Rasheed NM, Attia HA, Al-Amin MA, Al-Ajmi HN, Hasan IH, Mohamad RA, Sinjilawi NA: Renoprotective effects of fenofibrate via modification of LKB1/AMPK mRNA expression and endothelial dysfunction in a rat model of diabetic nephropathy. Pharmacol Res 65:229–239, 2012

Hong YA, Lim JH, Kim MY, Kim TW, Kim Y, Yang KS, Park HS, Choi SR, Chung S, Kim HW, Kim HW, Choi BS, Chang YS, Park CW: Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1alpha in db/db mice. PLoS One 9:e96147, 2014

Liu Y, Li D, Zhang Y, Sun R, Xia M: Adiponectin increases adiponectin secretion and protects against diabetes-related endothelial dysfunction. Am J Physiol Endocrinol Metab 2014; 306:E975–E988

Valenti I, Riso P, Mazzocchi A, Perrini M, Fargion S, Agostoni C: Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease. Oxid Med Cell Longev 2013:145421, 2013

Koh ES, Lim JH, Kim MY, Chung S, Shin SJ, Choi BS, Kim HW, Hwang SY, Kim SW, Park CW, Chang YS: Anthocyanin-rich Soseirae extract ameliorates renal lipotoxicity via activation of AMP-activated protein kinase in diabetic mice. J Transl Med 13:204, 2015

Massy ZA, Henaux L, Larsson TE, Vervloet MG: Calcium-sensing receptor activation in chronic kidney disease: effects beyond parathyroid hormone control. Semin Nephrol 34:648–659, 2014

Thakore P, Ho WS: Vascular actions of calcimimetics: role of Ca(2+) sensing receptors versus Ca(2+) influx through L-type Ca(2+) channels. Br J Pharmacol 162:749–762, 2011

Bonomini M, Giardinelli A, Morabito C, Di Silvestre S, Di Cesare M, Di Pietro N, Siroli V, Formoso G, Amoroso L, Mariggio MA, Pandolfi A: Calcimimetic R-568 and its enantiomer S-568 increase nitric oxide release in human endothelial cells. PLoS One 7:e30682, 2012

Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, Yamaguchi M, Tanabe H, Kimura-Someya T, Shirozu M, Ogata H, Tokuyama K, Ueki K, Nagano T, Tanaka A, Yokoyama S, Kadokawa T: A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 503:493–499, 2013

Holland WL, Scherer PE: Cell biology. Running after the adiponectin receptors. Science 342:1460–1461, 2013

Ealey KN, Kaludjerovic J, Archer MC, Ward WE: Adiponectin is a negative regulator of bone mineral and bone strength in growing mice. Exp Biol Med (Maywood) 233:1546–1553, 2008

Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akamura Y, Gavrilova V, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadokawa T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946, 2001

Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala MW, Parlow AF, Cheeseboro L, Ding YY, Russell RG, Lindemann D, Hartley A, Baker GR, Obici S, Deshaies Y, Ludgate M, Rossetti L, Scherer PE: A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145:367–383, 2004

Jin DC, Ha IS, Kim NH, Lee SW, Lee JS, Yoon SR, Kim BS: Brief report: renal replacement therapy in Korea, 2010. Kidney Res Clin Pract 31:62–71, 2012

Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Ealey KN, Kaludjerovic J, Archer MC, Ward WE: Adiponectin is a negative regulator of bone mineral and bone strength in growing mice. Exp Biol Med (Maywood) 233:1546–1553, 2008